

# Mastic Gum and Helicobacter Pylori eradication: an in vivo pilot study

**Submission date**  
31/03/2008

**Recruitment status**  
No longer recruiting

☐ Prospectively registered

☐ Protocol

**Registration date**  
29/04/2008

**Overall study status**  
Completed

☐ Statistical analysis plan

☒ Results

**Last Edited**  
20/09/2010

**Condition category**  
Infections and Infestations

☐ Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Konstantinos Dabos

**Contact details**  
Helenas Venizelou 2  
Chios  
Greece  
821-00  
kostasophia@yahoo.com

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
MGHP05

## Study information

**Scientific Title**

**Acronym**

MGHP

**Study objectives**

Mastic gum is effective in eradicating *Helicobacter pylori* in vivo.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics approval received from the Greek Medicines Agency Ethics Board on the 18th December 2005 (ref: MGCGH0032/06).

**Study design**

Randomised controlled trial with three arms

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet****Health condition(s) or problem(s) studied**

*Helicobacter pylori* gastritis

**Interventions**

Patients positive to *Helicobacter pylori* will be randomised to receive one of the following:

1. Mastic gum 2 g per day for 14 days
2. Mastic gum 2 g per day and pantoprazole 40 mg per day for 14 days
3. Pantoprazole 40 mg per day, amoxicillin 2 g per day and clarithromycin 1 g per day for 10 days

Follow up was two months after the end of the treatment for all study arms.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Mastic gum, pantoprazole, amoxicillin, clarithromycin

**Primary outcome measure**

Eradication of *Helicobacter pylori*, measured at five weeks after the end of treatment.

**Secondary outcome measures**

*Helicobacter pylori* load in patients remaining *H. pylori* positive, measured at five weeks after the end of treatment.

**Overall study start date**

01/12/2006

**Completion date**

01/06/2007

## Eligibility

**Key inclusion criteria**

1. Patients tested positive for *H. pylori*
2. Adults of either sex aged between 18 and 75 years of age

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

75 Years

**Sex**

Both

**Target number of participants**

42

**Key exclusion criteria**

1. Pregnancy
2. Malignancy
3. Allergies to pantoprazole, amoxicillin, clarithromycin

**Date of first enrolment**

01/12/2006

**Date of final enrolment**

01/06/2007

# Locations

## Countries of recruitment

Greece

## Study participating centre

**Helenas Venizelou 2**

Chios

Greece

821-00

# Sponsor information

## Organisation

The Chios Mastic Gum Producers Cooperative (Greece)

## Sponsor details

Konstantinou Monomahou 1

Chios

Greece

821-00

## Sponsor type

Industry

## Website

<http://www.gummastic.gr>

## ROR

<https://ror.org/05rpby975>

# Funder(s)

## Funder type

Industry

## Funder Name

The Chios Mastic Gum Producers Cooperative (Greece)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | results | 01/03/2010   |            | Yes            | No              |